6:05 PM
 | 
Dec 01, 2017
 |  BioCentury  |  Product Development

PAIRing up in Parkinson’s

How Pfizer’s work with Parkinson’s advocates led to simpler trials, focused PROs

A research partnership with the Parkinson’s Foundation helped Pfizer Inc. streamline a clinical program in Parkinson’s disease and identify outcomes to measure that are more in line with patients’ priorities.

As a result of the collaboration, Pfizer reports that study enrollment has been faster than expected.

The Parkinson’s Foundation’s mission includes investing in and advocating for research to end the disease and improve quality of life for patients and their families. To that end, it trains and helps connect patient and caregiver advocates to researchers in academia, government or industry who are seeking patient perspectives on their projects.

“If we added that expertise to that of researchers conducting clinical trials it could really improve them, and get to the therapies we would like to more quickly,” said Karlin Schroeder, director of community engagement at the foundation.

The PAIR curriculum includes two and a half days of sessions with faculty from FDA, academia and industry covering the phases of research, informed consent and ethics, how to understand research results and skills needed to represent the perspectives and priorities of the community.

“If we added that expertise to that of researchers conducting clinical trials it could really improve them.”

Karlin Schroeder, Parkinson’s Foundation

PAIR advocates have served on FDA advisory committees, clinical study IRBs and DSMBs....

Read the full 1047 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >